LGALS3 and fibrosis: Furthermore, recent studies indicate that Gal-3 is involved in cardiovascular fibrosis as a regulatory molecule in heart failure and, thus, that Gal-3 inhibition ameliorates myocardial injury, highlighting its therapeutic potential [53,54].